GLP-1 [S] (5mg)

Semaglutide is a blockbuster metabolic peptide developed by Novo Nordisk that fundamentally changed how the medical world treats type 2 diabetes and obesity. It operates as a GLP-1 (Glucagon-like peptide-1) receptor agonist, mimicking a natural gut hormone to regulate appetite and blood sugar.

Depending on the specific medical goal and formulation, it is sold under three major brand names:

• Ozempic (Injectable): FDA-approved for Type 2 Diabetes and to reduce major cardiovascular risks in those patients.

• Wegovy (Injectable or Oral Pill): FDA-approved for Chronic Weight Management, reducing cardiovascular risk in patients with overweight/obesity, and treating MASH (metabolic dysfunction-associated steatohepatitis/fatty liver disease).

• Rybelsus (Oral Pill): FDA-approved for Type 2 Diabetes and cardiovascular risk reduction.

How It Works in the Body

When you eat, your gut naturally releases GLP-1 to signal to your body that food has arrived. Natural GLP-1 is destroyed by enzymes within minutes. Semaglutide is structurally modified to resist this breakdown, allowing it to circulate and work continuously in the body.

• Brain Appetite Suppression: It targets the receptors in the brain that control hunger and cravings, drastically lowering "food noise" (the constant, intrusive thoughts about food).

• Delayed Gastric Emptying: It slows down the speed at which your stomach empties its contents. This physical delay keeps you feeling full on significantly smaller portions of food.

• Glucagon & Insulin Optimization: It triggers the pancreas to release insulin only when blood sugar rises, while suppressing glucagon (a hormone that tells your liver to dump excess sugar into the blood).

The Big Evolution: Injectable vs. The New Wegovy Pill

For years, semaglutide for weight loss was strictly an injectable medication. However, a massive shift occurred with the launch of the oral Wegovy 25 mg pill.

Backed by the landmark OASIS-4 clinical trial, this once-daily tablet proved that needle-free weight management could stand toe-to-toe with injections.

Expanded Medical Indications (Beyond Weight Loss)

Semaglutide is no longer viewed as just a weight-loss tool; it is a multi-organ health therapy. Clinical data has pushed the FDA to approve it for several major health conditions:

• Cardiovascular Protection: Large-scale trials (like the SELECT trial) proved semaglutide reduces the risk of heart attacks, strokes, and cardiovascular death by 20% in adults with established heart disease and obesity.

• MASH / Fatty Liver Disease: Wegovy holds accelerated FDA approval for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver scarring, helping clear fat accumulations from liver tissue.

• Chronic Kidney Disease (CKD): Following the groundbreaking FLOW trial—which was stopped early because the drug was too effective—semaglutide is approved to slow down kidney function decline and reduce kidney failure risks in patients with type 2 diabetes.

Side Effects & Safety Realities

The primary downside of semaglutide remains gastrointestinal. Nausea, vomiting, diarrhea, constipation, and acid reflux are common, particularly when first starting or escalating doses.